Amgen stock price jumps as earnings beat puts MariTide obesity bet back in focus
Amgen shares jumped 8.5% to $367.52 in afternoon trading Tuesday, outpacing a broader market decline. The company reported Q4 revenue up 9% to $9.9 billion and projected 2026 sales as high as $38.4 billion. Investors focused on late-stage trials for obesity drug MariTide. The FDA has requested withdrawal of Tavneos, but Amgen is refusing.